NCT03834662View on ClinicalTrials.gov

A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 7, 2019

Primary Completion Date

February 19, 2020

Study Completion Date

February 19, 2020

Conditions
Malignant Solid Tumor
Interventions
DRUG

AVID200

A TGFβ receptor ectodomain-IgG Fc fusion protein inhibitor of TGFβ

Trial Locations (3)

49546

START Midwest Clinic, Grand Rapids

77030

MD Anderson Cancer Center, Houston

M5G 1Z5

Princess Margaret Cancer Centre, Toronto

Sponsors

Collaborators (1)

Formation Biologics
All Listed Sponsors
collaborator

Formation Biologics

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY

NCT03834662 - A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies | Biotech Hunter | Biotech Hunter